* ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.Development Funding Loan Agreement • August 9th, 2024 • Cytokinetics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2024 Company Industry JurisdictionTHIS 2024 DEVELOPMENT FUNDING LOAN AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of May 22, 2024 (the “Effective Date”) among ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and a Lender and together with RP’s affiliates, successors and/or assignees that become a Lender or lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 350 Oyster Point Boulevard, South San Francisco, CA 94080 (“Company”), provides the terms on which the Lenders shall lend or otherwise provide financing to Company and Company shall repay the Lenders.
CK-586 Revenue Participation Right Purchase Agreement By and Between Cytokinetics, Incorporated and Royalty Pharma Investments 2019 ICAV Dated as of May 22, 2024Revenue Participation Right Purchase Agreement • August 9th, 2024 • Cytokinetics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2024 Company Industry JurisdictionThis CK-586 Revenue Participation Right Purchase Agreement, dated as of May 22, 2024, (this “Agreement”), is made and entered into by and between Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), and Cytokinetics, Incorporated, a Delaware corporation (the “Seller”).
CYTOKINETICS, INCORPORATED COMMON STOCK OPTION PURCHASE AGREEMENTCommon Stock Option Purchase Agreement • August 9th, 2024 • Cytokinetics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2024 Company Industry JurisdictionTHIS COMMON STOCK OPTION AND PURCHASE AGREEMENT (the “Agreement”) is made as of May 22, 2024 (the “Execution Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the “Company”), and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Investor”). Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the CK-586 Purchase Agreement (defined below).
AMENDMENT NO. 1 TO REVENUE PARTICIPATION RIGHT PURCHASE AGREEMENTRevenue Participation Right Purchase Agreement • August 9th, 2024 • Cytokinetics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2024 Company Industry JurisdictionThis Amendment No. 1 To Revenue Participation Right Purchase Agreement, dated as of May 22, 2024 (this “Amendment”), is made and entered into by and between Cytokinetics, Incorporated, a Delaware corporation (the “Seller”), and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”).